At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02197 CLOVER BIO-B
Pre-opening 12-23 09:25:42
2.410
+0.000
0.00%
High2.410
Low2.410
Vol0.00
Open2.410
D1 Closing2.410
Amplitude0.00%
Mkt Cap3.13B
Tradable Cap3.13B
Total Shares1.30B
T/O0.00
T/O Rate0.00%
Tradable Shares1.30B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled
CLOVER BIO-B (02197) Announces Positive Phase I Clinical Trial Data for Respiratory Combination Vaccine (RSV-hMPV-PIV3) and RSV Vaccine Booster in Elderly Population
Hong Kong Stock Alert | CLOVER BIO-B (02197) Surges Over 21% Following Announcement of Phase I Clinical Trial Launch for Respiratory Combination Vaccine Candidates
HK Movers | Biotech Stocks Plunge. Ascletis Pharma down 14%; Clover Bio, Transcenta down over 10%; Beigene, HBM Holdings down over 8%; Jacobio down over 7%
Hong Kong Stocks Movement | CLOVER BIO-B (02197) Falls Over 9% After Earnings Release, Interim Adjusted Loss of RMB 97.638 Million, Up 11.89% Year-over-Year
Clover Biopharmaceuticals Ltd is an investment holding company primarily engaged in the research and development, manufacture and commercialization of innovative vaccines. The Company’s products and candidates include Respiratory Syncytial Virus (RSV) Vaccine (SCB-1019), seasonal quadrivalent influenza vaccine AdimFlu-S, SCB-219M, COVID-19 Vaccine and others. The Company leverages the Trimer-Tag technology platform to conduct research and development (R&D) for innovative vaccines that can fulfill unmet need, with a focus on building a respiratory vaccine franchise and establishing a presence in the pediatric vaccine market. The Trimer-Tag is a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets. The Company conducts its business in the domestic and overseas markets.